Baxfendy (baxdrostat)
AstraZeneca (AZN)
ApprovedMay 15, 2026
Marketer take
An aldosterone synthase inhibitor for add-on hypertension, a crowded primary-care market where payer access drives uptake, and Mineralys' lorundrostat decision on Dec 22, 2026 sets up a same-class rival.
- Sponsor company
- AstraZeneca (AZN)
- Indication
- To treat hypertension in combination with other antihypertensive drugs
- Therapeutic area
- Cardiovascular
- Event
- FDA approval
- Date
- May 15, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?